Turn Therapeutics expands GX-03 Phase 2 after positive interim results in broader AD population
Aug 12, 2026, 4:39 PM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
Interim Phase 2 data show meaningful treatment separation and a larger eligible population, which could expand TAM and future trial catalysts. Positive leadership alignment (Hahn) and HS expansion add optionality; cash runway supports execution, reducing funding risk. Historical parallels: biotech catalysts tied to interim efficacy and leadership signals often precede re-ratings on enrollment progress.
AI summary
What happened, with direct paths to the underlying reporting
Turn Therapeutics reports interim GX-03 Phase 2 data showing activity across a broader atopic dermatitis population, including moderate-to-severe lesions with lower EASI scores. The company expanded Stage 2 to 120–135 patients and appointed Dr. Stephen Hahn to lead clinical/regulatory work, while planning a hidradenitis suppurativa program with first patient dosing in 2027. Cash runway extends into 3Q 2027.
Interim GX-03 Phase 2 shows activity across a broader AD population, including lower EASI.
Stage 2 expanded to ~120–135 patients with 99.8% power across four endpoints.
Dr. Stephen Hahn named Executive Clinical and Regulatory Lead to guide development.
First peer-reviewed publication shows GX-03 reducing inflammation in preclinical IL-36 model.
GX-03 HS expansion planned; first patient dosing targeted for Q2 2027.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
